First Look at TALAPRO-3 Results: Dr. Andrew Armstrong on Top ASCO26 Research

Added: 2026-06-03

[00:00:03][music] [music] >> I'm Andrew Armstrong at Duke University.

[00:00:17]I'm excited to share the sneak preview of the Talapro 3 dataset.

[00:00:21]Talapro 3 enrolled 599 men with metastatic androgen pathway modulator sensitive or hormone sensitive prostate cancer.

[00:00:32]And they were randomized to talazoparib and enzalutamide or enzalutamide, which has been an effective standard of care for these patients with newly diagnosed metastatic disease.

[00:00:43]The Talapro 3 patients were enrolled based on the presence of a homologous repair deficiency, so such as BRCA2 mutations either germline or somatic.

[00:00:55]Talazoparib is a selective PARP1/2 inhibitor that's already FDA approved in a more late-line setting. The Talapro 3 trial was a positive study. It significantly delayed the primary endpoint of radiographic progression-free survival, particularly in the BRCA2 mutated patients with a hazard ratio that was around 0.37.

[00:01:18]But more notably, it was also positive in the non-BRCA patients where the hazard ratio for delaying progression-free survival was around 0.57.

[00:01:29]There was a favorable trend for overall survival.

[00:01:32]And we see notable side effects of anemia as well as drops in blood counts and fatigue, but no new safety signals were identified.

[00:01:43]This represents an important landmark as we've seen from the amplitude study that the role of PARP inhibition in the earlier hormone-sensitive setting is particularly effective, particularly in BRCA mutated patients, but this is really the first study to demonstrate clinical utility in both bracket mutated and non-bracket mutated patients with homologous repair deficiencies. So, an exciting day at ASCO.